Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Drug

Innorna’s IN013 Receives FDA Rare Pediatric Designation for Wilson’s Disease Treatment

Fineline Cube Feb 24, 2025

Shenzhen-based Innorna Co., Ltd, a platform company leveraging mRNA and lipid nanoparticle (LNP) delivery technologies,...

Company Deals

Amoytop Biotech to Acquire Skyline Therapeutics’ Gene Therapy Assets for $15M Plus Milestones

Fineline Cube Feb 24, 2025

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced plans to acquire partial assets of...

Company

Novo Nordisk’s Emerging Business Division VP Eve Jiang Departs for External Opportunities

Fineline Cube Feb 24, 2025

Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business...

Company Drug

Joyo Pharma’s JYP0015 Receives CDE Approval for RAS Mutation Cancer Trials

Fineline Cube Feb 24, 2025

China’s Center for Drug Evaluation (CDE) has tacitly approved Joyo Pharma’s Category 1 drug JYP0015,...

Company Drug

Zhejiang Huahai Pharma’s HB0056 Receives NMPA Approval for Asthma Trials

Fineline Cube Feb 24, 2025

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that its bispecific antibody HB0056 has...

Company Drug

Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease

Fineline Cube Feb 24, 2025

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a...

Company Deals

Grand Pharmaceutical to Boost Stake in Nanjing Kainite Medical Technology via Exercise of Partial Subscription Rights

Fineline Cube Feb 24, 2025

Grand Pharmaceutical Group Limited (HKG: 0512) announced on February 21, 2025, that it plans to...

Company Drug

Coherent Biopharma’s CBP-1019 Granted FDA Fast Track Status for Endometrial Cancer

Fineline Cube Feb 24, 2025

Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), announced that the U.S....

Company Drug

Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress

Fineline Cube Feb 24, 2025

Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...

Company Drug

Triastek’s 3D-Printed Drug D23 Shows Promise in Treating IgA Nephropathy

Fineline Cube Feb 24, 2025

China-based Triastek Inc., a pioneer in pharmaceutical 3D printing, announced positive outcomes from a clinical...

Company Drug

J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction

Fineline Cube Feb 24, 2025

U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase...

Company Medical Device

MicroPort CardioFlow’s AnchorMan LAA Occluder System Earns CE Mark Approval

Fineline Cube Feb 24, 2025

Hong Kong-listed MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has received the CE mark for...

Company Drug

AIM Vaccine Leverages DeepSeek AI to Optimize mRNA Shingles Vaccine Design

Fineline Cube Feb 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has filed its mRNA-based shingles vaccine with the...

Company Drug

Innovent Biologics’ Ipilimumab NDA Accepted by CDE with Priority Review for Colon Cancer

Fineline Cube Feb 24, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the Center for Drug Evaluation (CDE), National...

Policy / Regulatory

AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments

Fineline Cube Feb 23, 2025

The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...

Policy / Regulatory

In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications

Fineline Cube Feb 22, 2025

The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...

Policy / Regulatory

State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms

Fineline Cube Feb 22, 2025

The State Council has released a second draft proposal outlining measures to support the high-quality...

Company Medical Device

Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing

Fineline Cube Feb 22, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing...

Policy / Regulatory

Shanghai Issues Legal Guidebook for Innovative Drug Marketing

Fineline Cube Feb 22, 2025

The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...

Policy / Regulatory

China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation

Fineline Cube Feb 22, 2025

The Chinese government has released a set of opinions detailing the establishment of a new...

Posts pagination

1 … 238 239 240 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.